JP2025011178A5 - - Google Patents

Info

Publication number

JP2025011178A5

JP2025011178A5 JP2024174919A JP2024174919A JP2025011178A5 JP 2025011178 A5 JP2025011178 A5 JP 2025011178A5 JP 2024174919 A JP2024174919 A JP 2024174919A JP 2024174919 A JP2024174919 A JP 2024174919A JP 2025011178 A5 JP2025011178 A5 JP 2025011178A5

Authority

JP

Japan

Prior art keywords

pharmaceutical composition

amino acid

acid sequence

antibody

seq

Prior art date

2024-10-04

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000008194 pharmaceutical composition Substances 0.000 claims 36
• 125000003275 alpha amino acid group Chemical group 0.000 claims 20
• 102100038449 Claudin-6 Human genes 0.000 claims 13
• 101000882898 Homo sapiens Claudin-6 Proteins 0.000 claims 13
• 210000004027 cell Anatomy 0.000 claims 12
• 201000011510 cancer Diseases 0.000 claims 11
• 206010028980 Neoplasm Diseases 0.000 claims 9
• 150000003839 salts Chemical class 0.000 claims 9
• 238000002512 chemotherapy Methods 0.000 claims 8
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 4
• 229960004316 cisplatin Drugs 0.000 claims 4
• 150000007523 nucleic acids Chemical group 0.000 claims 4
• 230000004048 modification Effects 0.000 claims 3
• 238000012986 modification Methods 0.000 claims 3
• 108010006654 Bleomycin Proteins 0.000 claims 2
• 229930012538 Paclitaxel Natural products 0.000 claims 2
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 2
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 2
• 229960001561 bleomycin Drugs 0.000 claims 2
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 2
• 229960004562 carboplatin Drugs 0.000 claims 2
• 239000012829 chemotherapy agent Substances 0.000 claims 2
• 230000004540 complement-dependent cytotoxicity Effects 0.000 claims 2
• 235000018417 cysteine Nutrition 0.000 claims 2
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 2
• 230000009089 cytolysis Effects 0.000 claims 2
• 229960004679 doxorubicin Drugs 0.000 claims 2
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 2
• 229960005420 etoposide Drugs 0.000 claims 2
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
• 229960005277 gemcitabine Drugs 0.000 claims 2
• 230000001404 mediated effect Effects 0.000 claims 2
• 238000011395 multi-agent chemotherapy Methods 0.000 claims 2
• 102000039446 nucleic acids Human genes 0.000 claims 2
• 108020004707 nucleic acids Proteins 0.000 claims 2
• 229960001592 paclitaxel Drugs 0.000 claims 2
• 238000006467 substitution reaction Methods 0.000 claims 2
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
• UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 2
• 229960000303 topotecan Drugs 0.000 claims 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
• 108010047041 Complementarity Determining Regions Proteins 0.000 claims 1
• 101710160107 Outer membrane protein A Proteins 0.000 claims 1
• 206010038111 Recurrent cancer Diseases 0.000 claims 1
• 230000000259 anti-tumor effect Effects 0.000 claims 1
• 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 1
• 239000000969 carrier Substances 0.000 claims 1
• 231100000433 cytotoxic Toxicity 0.000 claims 1
• 230000001472 cytotoxic effect Effects 0.000 claims 1
• 239000003085 diluting agent Substances 0.000 claims 1
• 239000012636 effector Substances 0.000 claims 1
• 230000002708 enhancing effect Effects 0.000 claims 1
• 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
• 230000006882 induction of apoptosis Effects 0.000 claims 1
• 230000002401 inhibitory effect Effects 0.000 claims 1
• 230000005764 inhibitory process Effects 0.000 claims 1
• 239000002502 liposome Substances 0.000 claims 1
• 208000037819 metastatic cancer Diseases 0.000 claims 1
• 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
• 239000000546 pharmaceutical excipient Substances 0.000 claims 1
• 239000003755 preservative agent Substances 0.000 claims 1
• 230000035755 proliferation Effects 0.000 claims 1
• 239000000126 substance Substances 0.000 claims 1
• 239000013598 vector Substances 0.000 claims 1
• 239000003981 vehicle Substances 0.000 claims 1